Evidence map›Paper›PMID 39641282›Full record

ReviewEpilepsia open2025

Exploring ketogenic diet resistance in glucose transporter type 1 deficiency syndrome: A comprehensive review and critical appraisal.

Raffaele Falsaperla, Vincenzo Sortino, Gerhard Josef Kluger, Thomas Herberhold, Andrea Rüegger, Pasquale Striano, Martino Ruggieri, Joerg Klepper, Georgia Ramantani

Abstract readReview
In one paragraph

Review in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Toward a working definition of ketogenic diet resistance in GLUT1 deficiency syndrome.Epileptic disorders : international epilepsy journal with videotape · 2025
    Review
  4. Article
  5. Review
  6. Status epilepticus in the neonate.BMJ paediatrics open · 2025
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raffaele FalsaperlaNeonatal Intensive Care Unit and Neonatal Accompaniment Unit, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco," San Marco Hospital, University of Catania, Catania, Italy.ORCID 0000-0002-4482-3506
Vincenzo SortinoUnit of Pediatrics and Pediatric Emergency, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco," San Marco Hospital, University of Catania, Catania, Italy.
Gerhard Josef KlugerEpilepsy Center for Children and Adolescents, Schön Clinic Vogtareuth, Vogtareuth, Germany.
Thomas HerberholdClinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik Vogtareuth, Vogtareuth, Germany.
Andrea RüeggerDepartment of Neuropediatrics, University Children's Hospital Zurich, Zurich, Switzerland.
Pasquale StrianoPediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini", Full Member of ERN-Epicare, Genova, Italy.ORCID 0000-0002-6065-1476
Martino RuggieriUnit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy.
Joerg KlepperKlinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany.ORCID 0000-0003-3741-025X
Georgia RamantaniDepartment of Neuropediatrics, University Children's Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-7931-2327

Funding

Italian Ministry of Health RIN - RCR-2022-23682290National Recovery and Resilience Plan (NRRP), MNESYS (PE0000006)Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 208184
6 · The paper itself

Abstract

Glucose transporter type 1 deficiency syndrome (GLUT1DS) commonly presents with early-onset epilepsy that often resists conventional pharmacological treatment. Ketogenic diet therapy (KDT) is the preferred approach to address the underlying metabolic anomaly. However, a subset of GLUT1DS patients presents resistance to KDT, with the causes remaining elusive. This comprehensive literature review aims to explore the characteristics of KDT failure in GLUT1DS and identify risk factors within this population. Our goal is to improve counseling and prognostication for these patients. So, we conducted a comprehensive literature review on PubMed, focusing on studies documenting pediatric GLUT1DS patients with drug-resistant epilepsy unresponsive to KDT. We identified five cases of KDT failure in female GLUT1DS patients, aged 10 days to 13 years at diagnosis. Predominant seizure types were absence seizures, with a few cases of clonic, tonic, or myoclonic seizures. EEG consistently revealed 2-3.5 Hz generalized spike-and-wave discharges. Genetic investigations revealed point mutations and deletions in two cases each. Despite an in-depth search, no specific features were found to reliably distinguish KDT non-responders from responders, underscoring the need for further research. In cases of KDT ineffectiveness for seizure control in GLUT1DS patients, exploring alternative therapeutic strategies becomes imperative to managing symptoms while maintaining quality of life. Large-scale multicenter studies, facilitated through international collaborations like the European Network for Therapy in Rare Epilepsies (NETRE), hold promise in elucidating the complexities of this patient population and developing personalized therapeutic approaches. PLAIN LANGUAGE SUMMARY: Glucose transporter type 1 deficiency syndrome often causes difficult-to-treat epilepsy. The ketogenic diet works for many patients, but some do not respond. This review investigated cases of diet failure but could not identify common features among poor responders. Further research is needed to understand these cases and explore alternative treatments.

Indexed as

Carbohydrate Metabolism, Inborn ErrorsDiet, KetogenicDrug Resistant EpilepsyMonosaccharide Transport ProteinsAdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornMonosaccharide Transport Proteinsdrug‐resistant epilepsyGLUT1DSketogenic diet therapiesmetabolic diseaseresistance

Identifiers

PMID39641282
PMCPMC11803274

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.